<DOC>
	<DOCNO>NCT00005596</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know regimen chemotherapy effective acute lymphoblastic leukemia . PURPOSE : This randomized phase III trial compare four regimen combination chemotherapy see well work treat child newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine multidrug delayed-intensification therapy improve outcome child newly diagnose standard-risk acute lymphocytic leukemia . - Compare efficacy toxicity methotrexate administer 4 hour vs methotrexate administer 24 hour patient population . - Determine correlation event-free survival , minimal residual disease , early response patient population treat multiple drug regimen . OUTLINE : This randomize , multicenter study . - Induction ( week 1-4 ) : Patients receive induction therapy POG 9900 . - Consolidation ( week 5-32 ) : Patients randomize one four treatment arm . Patients ( 1 ; 19 ) randomize either arm III arm IV . - Arm I ( week 5-24 ) : Patients receive IT methotrexate ( MTX ) day 1 follow MTX IV 20 minute follow MTX continuously 23.6 hour week 7 , 10 , 13 , 16,19 , 22 . At 42 hour begin MTX infusion , patient receive oral leucovorin calcium every 6 hour total 3 dos . Patients also receive oral mercaptopurine daily begin week 5 continue completion consolidation therapy ; oral dexamethasone twice daily day 1-7 week 8 17 ; vincristine IV day 1 week 8 , 9 , 17 , 18 . - Arm II ( week 5-24 ) : Patients receive MTX IV 4 hour week 7 , 10 , 13 , 16 , 19 , 22 . At 42 hour begin MTX infusion , patient receive oral leucovorin calcium arm I . Patients also receive mercaptopurine , dexamethasone , vincristine , IT MTX arm I . - Arm III ( week 5-32 ) : Patients receive MTX IV arm I week 7 , 10 , 13 , 24 , 27 , 30 ; leucovorin calcium arm I ; pegaspargase IM day 2 , 3 , OR 4 week 16 ; oral mercaptopurine daily week 5-13 , week 24 completion consolidation therapy . Patients also receive IT MTX arm I week 7 , 10 , 13 , 16 , 20 , 21 , 30 ; oral dexamethasone twice daily week 8 , 16-18 , 28 total 35 day ; vincristine IV day 1 week 8 , 9 , 16 , 17 , 18 , 28 , 29 ; daunorubicin IV day 1 week 16-18 ; cyclophosphamide IV 30 minute day 1 week 20 ; cytarabine IV subcutaneously daily day 2-5 week 20 21 ; oral thioguanine daily week 20-21 . - Arm IV ( week 5-32 ) : Patients receive MTX IV arm II week 7 , 10 , 13 , 24 , 27 , 30 ; leucovorin calcium arm I ; pegaspargase , mercaptopurine , IT MTX , dexamethasone , vincristine , daunorubicin , cyclophosphamide , cytarabine , thioguanine arm III . - Intensive continuation ( week 25-80 ) : At week 25-72 arm I II , week 33-80 arm III IV , patient receive oral MTX every 6 hour 4 dos week 1 , 3 , 5 , 7 , 9 , 11 ; oral mercaptopurine daily ; oral leucovorin calcium every 12 hour 2 dos begin 48 hour start MTX ; IT MTX vincristine IV day 1 week 12 ; oral dexamethasone twice daily day 1-7 , begin administration vincristine . Treatment repeat every 12 week 4 course . - Additional continuation ( week 73-130 ) : At week 73-130 arm I II , week 81-130 arm III IV , patient receive oral MTX weekly ; oral mercaptopurine daily ; vincristine IV day 1 every 12 week ; oral dexamethasone intensive continuation therapy ; IT MTX day 1 every 12 week , begin last week first course ( place oral MTX ) . Patients follow monthly 1 year , every 2 month 1 year , every 3 month 1 year , every 6 month 1 year , every 6-12 month 1 year . PROJECTED ACCRUAL : A total 1,014 patient accrue study within 3.22 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis newly diagnose Bprecursor acute lymphocytic leukemia Standard risk ( low , high , high risk ) Prior registration treatment POG 9900 Classification Study PATIENT CHARACTERISTICS : Age : 1 21 diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
</DOC>